X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA GLENMARK PHARMA ELDER PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x -0.2 14.4 - View Chart
P/BV x 0.1 3.8 2.6% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ELDER PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
GLENMARK PHARMA
Mar-17
ELDER PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs380993 38.3%   
Low Rs188729 25.8%   
Sales per share (Unadj.) Rs491.2325.5 150.9%  
Earnings per share (Unadj.) Rs-3.239.3 -8.1%  
Cash flow per share (Unadj.) Rs14.448.7 29.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5159.2 236.5%  
Shares outstanding (eoy) m20.54282.17 7.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.6 21.9%   
Avg P/E ratio x-89.321.9 -407.3%  
P/CF ratio (eoy) x19.717.7 111.4%  
Price / Book Value ratio x0.85.4 13.9%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m5,833242,991 2.4%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m2,17916,408 13.3%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m10,08991,857 11.0%  
Other income Rs m257374 68.7%   
Total revenues Rs m10,34692,230 11.2%   
Gross profit Rs m-79220,367 -3.9%  
Depreciation Rs m3612,644 13.7%   
Interest Rs m2,7562,373 116.1%   
Profit before tax Rs m-3,65315,724 -23.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-810 -458.6%   
Tax Rs m1253,827 3.3%   
Profit after tax Rs m-6511,088 -0.6%  
Gross profit margin %-7.822.2 -35.4%  
Effective tax rate %-3.424.3 -14.1%   
Net profit margin %-0.612.1 -5.4%  
BALANCE SHEET DATA
Current assets Rs m9,24068,746 13.4%   
Current liabilities Rs m9,99827,027 37.0%   
Net working cap to sales %-7.545.4 -16.5%  
Current ratio x0.92.5 36.3%  
Inventory Days Days4685 54.5%  
Debtors Days Days6096 62.7%  
Net fixed assets Rs m10,12424,132 42.0%   
Share capital Rs m206282 72.9%   
"Free" reserves Rs m5,58244,643 12.5%   
Net worth Rs m7,73444,925 17.2%   
Long term debt Rs m4,88945,363 10.8%   
Total assets Rs m22,882117,639 19.5%  
Interest coverage x-0.37.6 -4.3%   
Debt to equity ratio x0.61.0 62.6%  
Sales to assets ratio x0.40.8 56.5%   
Return on assets %11.811.4 102.8%  
Return on equity %-0.824.7 -3.4%  
Return on capital %22.319.1 116.5%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30756,152 0.5%   
Fx outflow Rs m1258,084 1.5%   
Net fx Rs m18148,068 0.4%   
CASH FLOW
From Operations Rs m11,7546,574 178.8%  
From Investments Rs m-561-7,124 7.9%  
From Financial Activity Rs m-6,7625,432 -124.5%  
Net Cashflow Rs m4,4321,992 222.4%  

Share Holding

Indian Promoters % 39.6 48.3 82.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 16.8 34.4 48.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.5 343.8%  
Shareholders   16,479 56,727 29.0%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS